Abstract
Women with vaginitis often present to primary care settings. The most common types of vaginitis are bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. Less commonly, vaginitis results from a noninfectious etiology. In addition to vaginitis, a woman presenting with vaginal discharge may have physiologic discharge, cervicitis, or pelvic inflammatory disease; it is critical to exclude an upper genital tract infection in women presenting with vaginal discharge. Clinical assessment includes a combination of history, exam, assessment of vaginal pH, the whiff test, microscopy, and/or point-of-care testing for the three common infectious causes. Yeast vaginitis and bacterial vaginosis often recur, necessitating review of contributing factors and consideration of long-term management. Although vulvar symptoms more commonly result from discharge originating from the vagina or cervix, primary vulvar processes also occur and can present with pruritus, burning pain, dyspareunia, dysuria, or rarely with bleeding or a palpable mass. Primary vulvar conditions include contact and allergic dermatitis, chronic vulvar dermatoses, vulvar malignancies, and vulvodynia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291(11):1368–79.
Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol. 2007;109(1):114–20.
Klebanoff MA, Nansel TR, Brotman RM, Zhang J, Yu KF, Schwebke JR, et al. Personal hygienic behaviors and bacterial vaginosis. Sex Transm Dis. 2010;37(2):94–9.
Bradshaw CS, Walker SM, Vodstrcil LA, Bilardi JE, Law M, Hocking JS, et al. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis. 2014;209(10):1562–72.
Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(Rr-03):1–137.
Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect. 2004;80(1):58–62.
Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis. 2008;47(11):1426–35.
Schwebke JR, Rivers C, Lee J. Prevalence of Gardnerella vaginalis in male sexual partners of women with and without bacterial vaginosis. Sex Transm Dis. 2009;36(2):92–4.
Mitchell C, Manhart LE, Thomas KK, Agnew K, Marrazzo JM. Effect of sexual activity on vaginal colonization with hydrogen peroxide-producing lactobacilli and Gardnerella vaginalis. Sex Transm Dis. 2011;38(12):1137–44.
Sobel JD. Vulvovaginal candidosis. Lancet (London, England). 2007;369(9577):1961–71.
Giraldo P, von Nowaskonski A, Gomes FA, Linhares I, Neves NA, Witkin SS. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol. 2000;95(3):413–6.
Wilson JF. In the clinic. Vaginitis and cervicitis. Ann Intern Med. 2009;151(5):ITC3-1–ITC3-15; Quiz ITC3-6.
Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93.
Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002;99(3):419–25.
Gandhi J, Chen A, Dagur G, Suh Y, Smith N, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704–11. https://doi.org/10.1016/j.ajog.2016.07.045.
University of Washington STD Prevention Training Center. UWPTC.org
CDC Image Library Centers for Disease Control (CDC) Public Health Image Library (PHIL). https://phil.cdc.gov/QuickSearch.aspx?key=true
Hainer BL, Gibson MV. Vaginitis. Am Family Physician. 2011;83(7):807–15.21.
Frobenius W, Bogdan C. Diagnostic value of vaginal discharge, wet mount and vaginal pH – an update on the basics of gynecologic infectiology. Geburtshilfe Frauenheilkd. 2015;75(4):355–66.
Lara-Torre E, Pinkerton JS. Accuracy of detection of trichomonas vaginalis organisms on a liquid-based papanicolaou smear. Am J Obstet Gynecol. 2003;188(2):354–6.
Wiese W, Patel SR, Patel SC, Ohl CA, Estrada CA. A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. Am J Med. 2000;108(4):301–8.
Brown HL, Fuller DD, Jasper LT, Davis TE, Wright JD. Clinical evaluation of affirm VPIII in the detection and identification of Trichomonas vaginalis, Gardnerella vaginalis, and Candida species in vaginitis/vaginosis. Infect Dis Obstet Gynecol. 2004;12(1):17–21.
Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev. 2009;3:Cd006055.
Amaya-Guio J, Viveros-Carreno DA, Sierra-Barrios EM, Martinez-Velasquez MY, Grillo-Ardila CF. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10:Cd011701.
Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Dis. 2012;39(10):822–30.
Marshall AO. Managing recurrent bacterial vaginosis: insights for busy providers. Sex Med Rev. 2015;3(2):88–92.29.
Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2001;4:Cd002845.
Gioia-Flynt L. Vaginitis. In: Stovall TL, Ling F, Zite N, Chuang A, Tillmanns T, editors. Gynecology for the primary care physician. Philadelphia, PA: Springer; Current Medicine Group LLC a division of Springer Science+Business Media LLC. 2nd ed; 2008.
Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003;189(5):1297–300.
CDC phone and website to obtain assistance with nitroimidazole-resistant T. vaginalis (i.e. susceptibility testing and treatment of infected persons); 404–718–4141. https://www.cdc.gov/laboratory/specimensubmission/detail.html?CDCTestCode=CDC-10239
Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–86.
McClelland RS, Richardson BA, Hassan WM, Chohan V, Lavreys L, Mandaliya K, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis. 2008;197(10):1361–8.
Bradshaw CS, Vodstrcil LA, Hocking JS, Law M, Pirotta M, Garland SM, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis. 2013;56(6):777–86.
Brooks JP, Edwards DJ, Blithe DL, et al. Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome. Contraception. 2017;95(4):405–13. https://doi.org/10.1016/j.contraception.2016.11.006.
Hellberg D, Nilsson S, Mårdh PA. Bacterial vaginosis and smoking. Int J STD AIDS. 2000;11(9):603–6.
Brotman RM, Klebanoff MA, Nansel TR, et al. A longitudinal study of vaginal douching and bacterial vaginosis--a marginal structural modeling analysis. Am J Epidemiol. 2008;168(2):188–96. https://doi.org/10.1093/aje/kwn103.
Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905–27. https://doi.org/10.3109/1040841X.2015.1091805. Review.
Donders GG, Prenen H, Verbeke G, Reybrouck R. Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol. 2002;187(4):989–93.
Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.
Dennerstein GJ. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. J Reprod Med. 1986;31(9):801–3.
Hu H, Merenstein DJ, Wang C, et al. Impact of eating probiotic yogurt on colonization by Candida species of the oral and vaginal mucosa in HIV-infected and HIV-uninfected women. Mycopathologia. 2013;176(3–4):175–81. https://doi.org/10.1007/s11046-013-9678-4. Epub 2013 Aug 8.
Peterman TA, Tian LH, Metcalf CA, Satterwhite CL, Malotte CK, DeAugustine N, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med. 2006;145(8):564–72.
Peterman TA, Tian LH, Metcalf CA, Malotte CK, Paul SM, Douglas JM Jr. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis. 2009;48(2):259–60.
Stemmer SM, Mordechai E, Adelson ME, Gygax SE, Hilbert DW. Trichomonas vaginalis is most frequently detected in women at the age of peri−/premenopause: an unusual pattern for a sexually transmitted pathogen. Am J Obstet Gynecol. 2018;218(3):328.e1–e13.
Ginocchio CC, Chapin K, Smith JS, Aslanzadeh J, Snook J, Hill CS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol. 2012;50(8):2601–8.
Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis. 1999;180(6):1863–8.
Bautista CT, Wurapa EK, Sateren WB, et al. Association of bacterial vaginosis with chlamydia and gonorrhea among women in the U.S. Army. Am J Prev Med. 2017;52(5):632–9. https://doi.org/10.1016/j.amepre.2016.09.016.
Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. 2002;34:519–22.
Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008;22(12):1493–501. https://doi.org/10.1097/QAD.0b013e3283021a37.
McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195(5):698–702.
Cohen CR, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 2012;9(6):e1001251. https://doi.org/10.1371/journal.pmed.1001251.
Sorvillo F, Smith L, Kerndt P, Ash L. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis. 2001;7(6):927–32. https://doi.org/10.3201/eid0706.010603.
Hay PE, Lamont RF, Taylor-Robinson D, et al. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ. 1994;308(6924):295–8.
Cotch MF, Pastorek JG 2nd, Nugent RP, Hillier SL, Gibbs RS, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis. 1997;24(6):353–60.
Nyirjesy P, Peyton C, Weitz MV, Mathew L, Culhane JF. Causes of chronic vaginitis: analysis of a prospective database of affected women. Obstet Gynecol. 2006;108(5):1185–91.
Reichman O, Sobel J. Desquamative inflammatory vaginitis. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1042–50. https://doi.org/10.1016/j.bpobgyn.2014.07.003.
Sobel JD. Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol. 1994;171(5):1215–20.
Sobel JD, Reichman O, Misra D, Yoo W. Prognosis and treatment of desquamative inflammatory vaginitis. Obstet Gynecol. 2011;117(4):850–5. https://doi.org/10.1097/AOG.0b013e3182117c9e.
Murphy R, Edwards L. Desquamative inflammatory vaginitis: what is it? J Reprod Med. 2008;53(2):124–8.
Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C, Günther V. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Women’s Health. 2015;7:305–13. https://doi.org/10.2147/IJWH.S68979. eCollection 2015. Review.
Lloyd J, Crouch NS, Minto CL, Liao LM, Creighton SM. Female genital appearance: “normality” unfolds. BJOG. 2005;112:643–6.
ACOG. Vaginal “rejuvenation” and cosmetic vaginal procedures. ACOG committee opinion no. 378. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2007;110:737–8. (Reaffirmed 2017).
Lew BL, Haw CR, Lee MH. Cutaneous drug eruption from cetirizine and hydroxyzine. J Am Acad Dermatol. 2004;50(6):953–6.
Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol. 2010;9(8):992–7.
Fischer GO. The commonest causes of symptomatic vulvar disease: a dermatologist’s perspective. Australas J Dermatol. 1996;37(1):12–8.
Farage MA. Vulvar susceptibility to contact irritants and allergens: a review. Arch Gynecol Obstet. 2005;272(2):167–72.
Woodruff CM, Trivedi MK, Botto N, Kornik R. Allergic contact dermatitis of the vulva. Dermatitis. 2018;29(5):233–43. https://doi.org/10.1097/DER.0000000000000339. Review.
Pichardo-Geisinger R. Atopic and contact dermatitis of the vulva. Obstet Gynecol Clin N Am. 2017;44(3):371–8. https://doi.org/10.1016/j.ogc.2017.05.003. Review.
Bauer A, Rodiger C, Greif C, Kaatz M, Elsner P. Vulvar dermatoses--irritant and allergic contact dermatitis of the vulva. Dermatology. 2005;210(2):143–9. Review.
Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol. 2015;151(10):1061–7. https://doi.org/10.1001/jamadermatol.2015.0643.
Meffert JJ, Davis BM, Grimwood RE. Lichen sclerosus. J Am Acad Dermatol. 1995;32(3):393–416; quiz 417–8. Review.
Thomas RH, Ridley CM, McGibbon DH, Black MM. Anogenital lichen sclerosus in women. J R Soc Med. 1996;89(12):694–8.
Simonetta C, Burns EK, Guo MA. Vulvar dermatoses: a review and update. Mo Med. 2015;112(4):301–7.
Bradford J, Fischer G. Management of vulvovaginal lichen planus: a new approach. J Low Genit Tract Dis. 2013;17(1):28–32. https://doi.org/10.1097/LGT.0b013e318258bf5b.
Cooper SM, Ali I, Baldo M, Wojnarowska F. The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: a case-control study. Arch Dermatol. 2008;144(11):1432–5. https://doi.org/10.1001/archderm.144.11.1432.
Simpson RC, Thomas KS, Leighton P, Murphy R. Diagnostic criteria for erosive lichen planus affecting the vulva: an international electronic-Delphi consensus exercise. Br J Dermatol. 2013;169(2):337–43. https://doi.org/10.1111/bjd.12334.
Machin SE, McConnell DT, Adams JD. Vaginal lichen planus: preservation of sexual function in severe disease. BMJ Case Rep. 2010;2010:bcr08.2009.2208.84.
Clayton R, Chaudhry S, Ali I, Cooper S, Hodgson T, Wojnarowska F. Mucosal (oral and vulval) lichen planus in women: are angiotensin-converting enzyme inhibitors protective, and beta-blockers and non-steroidal anti-inflammatory drugs associated with the condition? Clin Exp Dermatol. 2010;35(4):384–7. https://doi.org/10.1111/j.1365-2230.2009.03581.x. Epub 2009 Oct 23.85.
Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, Dutronc Y, Henneges C, Kornberg LJ, Menter A. Prevalence of genital psoriasis in patients with psoriasis. J Dermatolog Treat. 2018;29(8):754–60. https://doi.org/10.1080/09546634.2018.1453125.
Meeuwis KA, de Hullu JA, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Derm Venereol. 2011;91(1):5–11. https://doi.org/10.2340/00015555-0988.87.
Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015;28(3):158–65. https://doi.org/10.1111/dth.12222.
Lynch PJ. Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region. Dermatol Ther. 2004;17:8–19.
van der Meijden WI, Boffa MJ, Ter Harmsel WA, Kirtschig G, Lewis FM, et al. 2016 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2017;31(6):925–41. https://doi.org/10.1111/jdv.14096.
O’Connell TX, Nathan LS, Satmary WA, Goldstein AT. Non-neoplastic epithelial disorders of the vulva. Am Fam Physician. 2008;77(3):321–6. Review.
Chibnall R. Vulvar pruritus and lichen simplex chronicus. Obstet Gynecol Clin N Am. 2017;44(3):379–88. https://doi.org/10.1016/j.ogc.2017.04.003.
Creasman WT. New gynecologic cancer staging. Obstet Gynecol. 1990;75(2):287–8.
Arnold LD, Bachmann GA, Rosen R, Kelly S, Rhoads GG. Vulvodynia: characteristics and associations with comorbidities and quality of life. Obstet Gynecol. 2006;107(3):617–24.
Pukall CF, Goldstein AT, Bergeron S, Foster D, Stein A, et al. Vulvodynia: definition, prevalence, impact, and pathophysiological factors. J Sex Med. 2016;13(3):291–304. https://doi.org/10.1016/j.jsxm.2015.12.021. Review.
Weström LV, Willén R. Vestibular nerve fiber proliferation in vulvar vestibulitis syndrome. Obstet Gynecol. 1998;91(4):572–6.
Farmer MA, Taylor AM, Bailey AL, Tuttle AH, MacIntyre LC, et al. Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci Transl Med. 2011;3(101):101ra91. https://doi.org/10.1126/scitranslmed.3002613.
Bazin S, Bouchard C, Brisson J, Morin C, Meisels A, Fortier M. Vulvar vestibulitis syndrome: an exploratory case-control study. Obstet Gynecol. 1994;83(1):47–50.
Bouchard C, Brisson J, Fortier M, Morin C, Blanchette C. Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. Am J Epidemiol. 2002;156(3):254–61.
Reed BD, Harlow SD, Sen A, Edwards RM, Chen D, Haefner HK. Relationship between vulvodynia and chronic comorbid pain conditions. Obstet Gynecol. 2012;120(1):145–51. https://doi.org/10.1097/AOG.0b013e31825957cf.
Harlow BL, Stewart EG. Adult-onset vulvodynia in relation to childhood violence victimization. Am J Epidemiol. 2005;161(9):871–80.
Khandker M, Brady SS, Vitonis AF, Maclehose RF, Stewart EG, Harlow BL. The influence of depression and anxiety on risk of adult onset vulvodynia. J Womens Health (Larchmt). 2011;20(10):1445–51. https://doi.org/10.1089/jwh.2010.2661.
van Beekhuizen HJ, Oost J, van der Meijden WI. Generalized unprovoked vulvodynia; a retrospective study on the efficacy of treatment with amitriptyline, gabapentin or pregabalin. Eur J Obstet Gynecol Reprod Biol. 2018;220:118–21. https://doi.org/10.1016/j.ejogrb.2017.10.026.
Reed BD, Haefner HK, Sen A, Gorenflo DW. Vulvodynia incidence and remission rates among adult women: a 2-year follow-up study. Obstet Gynecol. 2008;112(2 Pt 1):231–7. https://doi.org/10.1097/AOG.0b013e318180965b.
Spoelstra SK, Borg C, Weijmar Schultz WC. Anticonvulsant pharmacotherapy for generalized and localized vulvodynia: a critical review of the literature. J Psychosom Obstet Gynaecol. 2013;34(3):133–8. https://doi.org/10.3109/0167482X.2013.823942.
Murina F, Graziottin A, Felice R, Radici G, Tognocchi C. Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. J Low Genit Tract Dis. 2013;17(2):111–6. https://doi.org/10.1097/LGT.0b013e3182652316.
ter Kuile MM, Weijenborg PT. A cognitive-behavioral group program for women with vulvar vestibulitis syndrome (VVS): factors associated with treatment success. J Sex Marital Ther. 2006;32(3):199–213.
De Andres J, Sanchis-Lopez N, Asensio-Samper JM, Fabregat-Cid G, Villanueva-Perez VL, et al. Vulvodynia--an evidence-based literature review and proposed treatment algorithm. Pain Pract. 2016;16(2):204–36. https://doi.org/10.1111/papr.12274. Review.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Review Questions
Review Questions
-
1.
Tamara is a 34-year-old woman who calls your office complaining of vaginal discharge that started 2 days ago. She tells you the discharge is thin, yellow, and malodorous. She denies dysuria and dyspareunia, but notes mild associated pruritus. She tells you she is sexually active with only her husband, and they do not use condoms. She also says that her symptoms are similar to when she had a bacterial vaginosis infection earlier this year, and you confirm in the medical record that she was diagnosed with bacterial vaginosis 6 months ago. She requests a prescription for oral metronidazole. What do you advise?
-
A.
An office visit is not required; prescribe metronidazole 500 mg orally twice daily for 7 days
-
B.
An office visit is not required; prescribe metronidazole vaginal gel 0.75%, 5 g intravaginally once nightly for 5 days
-
C.
An office visit is not required; prescribe clindamycin 2% cream, 1 applicatorful once nightly for 7 days
-
D.
Advise her to come to the office to be evaluated
The correct answer is D: Advise her to come to the office to be evaluated [1]. Bacterial vaginosis (BV) is typically associated with a thin, homogenous, malodorous discharge. It is not usually associated with any pain or pruritus. However, none of these symptoms are diagnostic of BV. While choices A and B are recommended treatment regimens for a confirmed diagnosis of BV, a proper evaluation that includes history, pelvic exam, and office microscopy is required to confirm the diagnosis and rule out cervicitis and PID. Choice C is an alternative treatment regimen for BV.
-
A.
-
2.
Sweta is a 37-year-old woman presenting for vaginal discharge. She complains of thick, white discharge associated with pruritus. She is not sexually active. She reports having three “yeast infections” in the last year and believes this is another one. You perform a pelvic exam and prepare a wet mount, confirming a diagnosis of vulvovaginal candidiasis. Sweta is frustrated by the recurrent infections and wants to know what can be done. What do you advise?
-
A.
Prescribe a single dose of oral fluconazole 150 mg; suppressive therapy is not indicated
-
B.
Prescribe three doses of oral fluconazole 150 mg separated by 72 h; suppressive therapy is not indicated
-
C.
Prescribe 10 days of a topical azole or oral fluconazole 150 mg, followed by oral fluconazole 150 mg once per week for 6 months
-
D.
Prescribe a single dose of oral fluconazole 150 mg, followed by oral fluconazole 150 mg once per week for 6 weeks
The correct answer is choice C. Prescribe 10 days of a topical azole or oral fluconazole 150 mg, followed by oral fluconazole 150 mg once per week for 6 months. This woman has complicated and recurrent VC, defined as ≥4 episodes per year. Given that she is frustrated by the frequent symptoms she should be offered a course of chronic therapy. For the management of recurrent VC, the Infectious Diseases Society of America recommends 10–14 days of induction therapy with a topical azole or oral fluconazole followed by 6 months of maintenance therapy consisting of oral fluconazole 150 mg once weekly [44]. A single dose of oral fluconazole (Choice A) would be the correct choice if this was an uncomplicated vulvovaginal candidiasis (VC) infection (e.g. ≤3 episodes per year, mild to moderate symptoms), and choice B would be the correct answer if this was only complicated VC and Sweta was not bothered by her symptoms.
-
A.
-
3.
A 20-year-old woman presents complaining of 5 days of severe vulvar pruritus. Following full evaluation, the two of you determine that it is from an allergic dermatitis resulting from an allergy to the deodorant in her feminine pads, which she used for the first time beginning 1 week ago. What do you recommend?
-
A.
She should soak in very warm baths for relief
-
B.
She should use a strong liquid soap to remove any residual antigen
-
C.
She should immediately cease and permanently avoid using this product (and perhaps all feminine products that contain deodorant)
-
D.
She should take diphenhydramine around-the-clock for relief of pruritus
The correct answer is C. Immediate and permanent avoidance of the culprit antigen is the cornerstone of treating allergic contact dermatitis. In addition, topical steroid ointments and, if needed, oral antihistamines are used. Warm baths would aggravate the pruritus; cool Sitz baths and compresses are helpful. Harsh soaps are never recommended on the vulva. Diphenhydramine would be too sedating for daytime use; the preferred antihistamines for pruritus are cetirizine in the daytime and hydroxyzine at night.
-
A.
-
4.
A 55-year-old woman presents for a “routine Pap smear.” She reports mild vulvar itching for the past year or two. Her vulva appears abnormal with diffuse pallor and thinning, and her labia minora appear markedly shrunken. You recommend:
-
A.
Referral to dermatology or gynecology
-
B.
Waiting for the results of her cervical cytology to determine the next step
-
C.
A trial of watchful waiting
-
D.
A trial of topical estrogen
The correct answer is A. This presentation is classic for lichen sclerosus, which presents with focal or diffusely pale vulvar mucosa that is either abnormally thick (early stage) or thin (later stage). LS requires treatment using ultrapotent topical corticosteroids plus close monitoring for the possible development of vulvar cancer. For this reason, patients with LS are usually managed by dermatologists or gynecologists. Cervical cytology has no bearing on the patient’s vulvar problem. Watchful waiting is inappropriate since without treatment the destruction of her vulvar anatomy will progress and the risk of vulvar cancer is increased. The patient’s exam findings, particularly the changes to her labia minora, are too dramatic to be consistent with the genitourinary syndrome of menopause.
-
A.
-
5.
A 75-year-old healthy woman presents complaining of several months of progressive burning “in my private parts.” Her exam is notable for erosions with white borders on her labia minora as well as in her vagina. The most likely etiology is:
-
A.
Genital psoriasis
-
B.
Lichen sclerosus
-
C.
Lichen simplex chronicus
-
D.
Lichen planus
The correct answer is D. The erosive form of lichen planus is the only chronic dermatosis of the vulva that also involves the vagina, and erosions with surrounding white reticular borders are characteristic. Psoriasis involves plaques (not erosions). Lichen sclerosus presents with pale mucosa that is either abnormally thick or thin. Lichen simplex chronicus presents with plaques, lichenification, excoriations, and broken-off hairs that all result from excessive scratching.
-
A.
-
6.
A 50-year-old healthy woman presents with vulvar pruritus. Her pelvic exam reveals several symmetric erythematous plaques with rounded borders on the outer (hair-bearing) aspects of the labia majora. No scale is seen. Which of the following is true?
-
A.
Examination of the scalp, gluteal cleft, umbilicus, and nails might uncover findings that support the diagnosis
-
B.
This cannot be psoriasis since no silvery scale is present
-
C.
Biopsy is needed to confirm the diagnosis
-
D.
These lesions are most likely malignant
The correct answer is A. The findings described are classic for psoriasis on the vulva; uncovering psoriasis elsewhere on the body would be supportive of the diagnosis. Due to the apposition of the skin and overall moist environment of the vulva, scale is frequently absent at this location. Biopsy is rarely needed to make the diagnosis of psoriasis, even when isolated to the vulva. Although malignancies on the vulva may present in any of a myriad of presentations, the symmetry of lesions makes this unlikely.
-
A.
-
7.
Your next patient is a 24-year-old woman who is new to you. In eliciting her medical history, you learn that she quit using contraception because she and her husband have not had intercourse in nearly a year due to entrance dyspareunia. She tearfully explains that she has seen two physicians for this problem but was told “everything is normal.” She has no other genital complaints and she is healthy overall. You advise:
-
A.
A referral for individual psychotherapy
-
B.
Couple’s counseling
-
C.
Diagnostic pelvic exam
-
D.
A trial of amitriptyline or gabapentin
The correct answer is C. This patient describes provoked vestibulodynia. Although the mucosa of the vaginal vestibule appears normal in women with this condition, gentle application of a cotton-tipped applicator to the vestibule may reproduce the patient’s pain, and this maneuver should be performed during the pelvic exam to make the diagnosis. Histologic studies indicate an increased number of nociceptors at the vestibule of affected women, and an important component of patient counseling is communicating that the condition is real. Treatment includes topical anesthetics applied to the vestibule 15–20 min before intercourse then washed off immediately prior to penetration. Referral for individual or couples’ counseling is premature given that any mood or relationship problems might promptly resolve with treatment of her vestibulodynia. Chronic pain medications are used for unprovoked vulvar pain, typically generalized unprovoked vulvodynia.
-
A.
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shroff, S., Ryden, J. (2020). Vaginitis and Vulvar Conditions. In: Tilstra, S.A., Kwolek, D., Mitchell, J.L., Dolan, B.M., Carson, M.P. (eds) Sex- and Gender-Based Women's Health. Springer, Cham. https://doi.org/10.1007/978-3-030-50695-7_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-50695-7_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-50694-0
Online ISBN: 978-3-030-50695-7
eBook Packages: MedicineMedicine (R0)